Recent News

• 08.24.2026 - BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
• 08.14.2026 - BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
• 07.28.2026 - BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
• 06.02.2026 - BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
• 05.28.2026 - BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
• 05.19.2026 - BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
• 05.15.2026 - BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
• 03.31.2026 - BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
• 02.26.2026 - Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
• 02.20.2026 - Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

Recent Filings

• 08.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2026 - 8-K Current report
• 08.14.2026 - EX-99.1 EX-99.1
• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 3 Initial statement of beneficial ownership of securities
• 06.02.2026 - EFFECT Notice of Effectiveness
• 06.01.2026 - CORRESP Correspondence